- This topic has 0 replies, 1 voice, and was last updated 9 years, 9 months ago by
.
-
Posts
-
Canon U.S.A. and Liquent Announce High-Volume Printing Solutions for the Pharmaceutical Industry
Liquent CoreDossier Now Supports Canon’s Market Share Leading imageRUNNER Devices
In Responding to the Needs of Pharmaceutical companies to affordably assemble and print complex regulatory, and mission critical documents, Canon U.S.A., Inc., an industry leader in networked imaging solutions, and Liquent, Inc., the global leader in regulatory publishing, intelligence, and intellectual property solutions, today announced Liquent’s flagship CoreDossier product support for Canon’s imageRUNNER line of high-volume printing devices.
Using CoreDossier Version 5.5.3, pharmaceutical and life science companies can now efficiently manage the process of submitting large technical documents in accordance with strict U.S., European, and Japanese requirements by printing them on Canon imageRUNNER 7200, 8500, 85, 105, 110, and Pro 150+ models. CoreDossier, in use at nearly 300 locations around the world, enables life sciences companies to assemble and organize large volumes of documents into compliant formats and then creates the appropriate output in both PDF and Postscript formats. Publications – or dossiers – created with Liquent’s products are often submitted to government agencies and include New Drug Applications, Common Technical Documents, Marketing Authorization Applications, and other reports.
- You must be logged in to reply to this topic.